TYME - Tyme Technologies: Killing Cancer By Compromising Tumor Cell Metabolism
- Tyme has a solid product candidate in pancreatic cancer.
- The company has no debt, strong IP, good insider interest.
- Current price is a little on the higher side for my comfort.
- This article was posted for TPT subscribers earlier this month.
For further details see:
Tyme Technologies: Killing Cancer By Compromising Tumor Cell Metabolism